When It's Not Alzheimer's: Differential Dx of Frontotemporal Lobar Degeneration
MRI Features of bvFTD
MRI features of bvFTD in 2 different patients. In panel A there is striking atrophy in the bilateral mesial frontal regions, including the anterior cingulate gyri. There are also finger-like periventricular FLAIR hyperintensities and enlargement of the sylvian fissures, particularly anteriorly. In panel B, the insular surface is relatively featureless with cortical thinning and sharp angular gyri.
FDG-PET Scan Features of bvFTD
FDG-PET scan features of bvFTD. FDG surface reconstructions of the right and left lateral cerebral hemispheres (A and B, respectively) and the left and right mesial cerebral hemispheres (C and D, respectively) demonstrate severe disproportionate FDG hypometabolism in the left frontal lobe and medial left temporal pole.
Temporal Variant FTLD
A patient with right temporal variant FTLD.
Frontotemporal lobar degeneration (FTLD) refers to a group of non-Alzheimer's dementias that cause portions of the frontal and temporal lobes to atrophy, leading to impairments in behavior, personality, language, and movement. FTLD is estimated to cause up to 10% of dementia cases, and it is the most common cause of dementia in individuals younger than 60 years old, with symptoms usually appearing between the ages of 50 and 60.
In people under the age of 65, FTLD is believed to be as common as Alzheimer's disease (AD), and therefore it may be mistaken for AD.
Read the associated article here.
Images courtesy of Melanie B. Shulman, MD and Richard J. Caselli, MD.
Neurology Advisor Articles
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Deep Brain Stimulation Improves Survival in Parkinson Disease
- Induced Hypertension Does Not Improve Outcomes in Subarachnoid Hemorrhage, Cerebral Ischemia
- Devices for Acute, Preventive Migraine Care Now Available
- Evolocumab FDA Approved for Stroke Prevention in Cardiovascular Disease
- Depression in Parkinson Disease Linked to Impaired White Matter Integrity